The TGA has approved the first ever treatment – eculizumab (Soliris) – for an MS-like disease known as neuromyelitis optica spectrum disorder (NMOSD).
MS Research Australia is advocating for the new treatment to be included on the PBS.
The International Progressive MS Alliance has convened a panel of experts to evaluate the potential of ‘neurofilament light’ (NfL) as a way to easily and reliably track MS progression.
MSWA is proud to support the International Progressive Alliance through an allocation in our MSRA funding.
Want to be part of the research? Find an MS trial to get involved in!
A treatment used for cancer, autologous haematopoietic stem cell transplant (AHSCT) has been used to treat MS for many years. A study has been ongoing from 2005 to 2016 to compare AHSCT with other MS therapies.
The results of this trial, which were published in January 2019, showed that some patients receiving AHSCT had improvements in disability scores and significantly fewer relapses compared to those on standard MS medications.
Professor Michael Pender and Professor Rajiv Khanna, of the QIMR Berghofer Medical Research Institute in Brisbane, have completed a small trial using adoptive T-cell immunology to target Epstein-Barr virus-infected B cells. Seven of 10 participants showed clinical improvements including reduction in disability and improvements in fatigue.
From 1 January 2019 people eligible for MAVENCLAD® for RRMS will pay a maximum of $39.50 per script, or $6.40 for concessional patients. Mavenclad® is used to treat people with relapsing remitting MS.
A study by researchers at Brigham and Women’s Hospital in Boston, Massachusetts, has found that herbicide linuron, may be an important environmental risk factor in the development of neurological diseases that include multiple sclerosis.
If you would like more information about specific research, email us at customerservice@mswa.org.au.
Click here to read the latest edition of Vitality – MSWA's monthly e-newsletter covering the latest articles relating to research, medical advancements and general wellbeing for people living with MS and other neurological conditions.